Erasca, Inc.
General ticker "ERAS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $503.9M (TTM average)
Erasca, Inc. follows the US Stock Market performance with the rate: 30.6%.
Estimated limits based on current volatility of 4.6%: low 17.49$, high 19.17$
Factors to consider:
- Total employees count: 126 (-2.3%) as of 2023
- Top business risk factors: Limited operating history, Regulatory and compliance, Inexperience in marketing and distribution, Fluctuating operating results, Labor/talent shortage/retention
- Current price 255.5% above estimated high
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.28$, 5.35$]
- 2026-12-31 to 2027-12-31 estimated range: [1.85$, 4.43$]
Financial Metrics affecting the ERAS estimates:
- Positive: with PPE of -8.0 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -9.52 <= 0.07
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 10.02 > -0.65
- Negative: Industry earnings per price (median), % of -14.62 <= 0
- Positive: Shareholder equity ratio, % of 82.08 > 64.25
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: negative Industry operating income (median)
- Negative: negative Industry operating cash flow (median)
Short-term ERAS quotes
Long-term ERAS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $141.53MM | $179.59MM | $131.41MM |
| Operating Income | $-141.53MM | $-179.59MM | $-131.41MM |
| Non-Operating Income | $16.48MM | $17.94MM | $6.86MM |
| R&D Expense | $103.82MM | $137.86MM | $92.85MM |
| Income(Loss) | $-125.04MM | $-161.65MM | $-124.55MM |
| Profit(Loss)* | $-125.04MM | $-161.65MM | $-124.55MM |
| Stockholders Equity | $316.69MM | $423.50MM | $325.17MM |
| Assets | $395.30MM | $502.53MM | $396.15MM |
| Operating Cash Flow | $-101.22MM | $-109.42MM | $-95.45MM |
| Capital expenditure | $1.77MM | $22.56MM | $0.13MM |
| Investing Cash Flow | $-91.22MM | $-156.62MM | $100.42MM |
| Financing Cash Flow | $1.29MM | $240.70MM | $1.10MM |
| Earnings Per Share** | $-0.83 | $-0.69 | $-0.44 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.